GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (STU:1S70) » Definitions » Accumulated other comprehensive income (loss)

Cartesian Therapeutics (STU:1S70) Accumulated other comprehensive income (loss) : €-4.24 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cartesian Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Cartesian Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was €-4.24 Mil.

Cartesian Therapeutics's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 (€-4.33 Mil) to Dec. 2023 (€-4.22 Mil) but then declined from Dec. 2023 (€-4.22 Mil) to Mar. 2024 (€-4.24 Mil).

Cartesian Therapeutics's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 (€-4.04 Mil) to Dec. 2022 (€-4.30 Mil) but then increased from Dec. 2022 (€-4.30 Mil) to Dec. 2023 (€-4.22 Mil).

Cartesian Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Cartesian Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Accumulated other comprehensive income (loss) Chart

Cartesian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.07 -3.75 -4.04 -4.30 -4.22

Cartesian Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.27 -4.24 -4.33 -4.22 -4.24

Cartesian Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Cartesian Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cartesian Therapeutics (STU:1S70) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (STU:1S70) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
TCRX OCUL ATAI LCTX MCRB ENTA EYPT SCPH RENB XOMA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RNAC:USA 1S7:Germany
Address
65 Grove Street, Watertown, MA, USA, 02472
Website
https://www.selectabio.com
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Cartesian Therapeutics (STU:1S70) Headlines

No Headlines